Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (13)

Cough (10)

Pneumonia (5)

Fatigue (5)

Headache (3)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 13
    records per page




    IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals

    Authors: Michal A Stanczak; David E Sanin; Petya Apostolova; Gabriele Nerz; Dimitrios Lampaki; Maike Hofmann; Daniel Steinmann; Robert Thimme; Gerhard Mittler; Cornelius F Waller; Edward J Pearce; Erika L Pearce

    doi:10.1101/2020.07.09.20148056 Date: 2020-07-10 Source: medRxiv

    Our understanding of severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) is still developing. We investigated seroprevalence SERO and immune responses in subjects professionally exposed to SARS-CoV-2 and their family members TRANS (155 individuals; ages TRANS 5-79 years). Seropositivity for SARS-CoV-2 spike glycoprotein aligned with PCR results that confirmed previous infection MESHD. Anti-spike IgG titers remained high 60 days post- infection MESHD and did not associate with symptoms, but spike-specific IgM did associate with malaise and fever MESHD fever HP. We found limited household transmission TRANS, with children TRANS of infected individuals seldomly seropositive, highlighting professional exposure as the dominant route of infection MESHD in our cohort. We analyzed PBMCs from a subset of seropositive and seronegative adults TRANS. TLR7 agonist- activation revealed an increased population of IL-6+TNF-IL-1{beta}+ monocytes, while SARS-CoV-2 peptide stimulation elicited IL-33, IL-6, IFNa2, and IL-23 expression in seropositive individuals. IL-33 correlated with CD4+ T cell activation in PBMCs from convalescent subjects, and was likely due to T cell-mediated effects on IL-33- producing cells. IL-33 is associated with pulmonary infection MESHD infection and chronic HP and chronic diseases MESHD like asthma MESHD asthma HP and COPD, but its role in COVID-19 is unknown. Analysis of published scRNAseq data of bronchoalveolar lavage fluid (BALF) from patients with mild to severe COVID-19 revealed a population of IL-33-producing cells that increases with disease MESHD. Together these findings show that IL-33 production is linked to SARS-CoV- 2 infection MESHD and warrant further investigation of IL-33 in COVID-19 pathogenesis and immunity.

    Possible COVID-19 recurrence MESHD in an older patient: a case report

    Authors: Antoine Garnier-Crussard; Marine Haution ; Mathilde Gueret-Du-Manoir ; Quitterie Reynaud ; Nathalie Freymond ; Maude Bouscambert-Duchamp ; Anne Conrad ; Claire Falandry

    doi:10.21203/rs.3.rs-34694/v1 Date: 2020-06-11 Source: ResearchSquare

    Background: Novel coronavirus (COVID-19) pandemic cause by Severe Acute Respiratory Syndrome MESHD Coronavirus-2 (SARS-CoV-2) threatens the world for few months. Few cases of prolonged positivity of viral tests and clinical recurrence MESHD of COVID-19 have been described. We report the case of a 78-year-old woman with metastatic breast cancer who developed possible COVID-19 recurrence MESHD in a post-acute and rehabilitation unit. Case presentation: A 78-year-old woman with metastatic breast cancer and hypertension MESHD hypertension HP developed COVID-19. After symptom improvement and RT-PCR negativation, she regained symptom ( fever MESHD fever HP, fall HP) and lymphopenia MESHD lymphopenia HP on Day 26 and we note a turned positive RT-PCR even though she was tested positive for antibody SERO against SARS-CoV-2. After the diagnosis of possible COVID-19 recurrence MESHD, she was transferred back to an acute “COVID-19” unit and she then quickly clinically recovered. Conclusions: This clinical case allows us to discuss the risk of recurrence MESHD and possible specific causes in older patients. Moreover, prolonged symptoms and lymphopenia MESHD lymphopenia HP could be associated to worse outcomes in older patients. Finally, at a collective level, even if traces TRANS of virus detected by RT-PCR were not necessarily correlated with the contagiousness, the importance of possible COVID-19 recurrence MESHD in the care pathway for older adults TRANS must be taken into account, since they are often surrounded by frail older people.

    Screening and Analysis of COVID-19 cases in non-epidemic areas: A Retrospective Study

    Authors: Yan Zhu; Yan Guo; Juan Ma; Mao-shi Li; Jia-fei Chen; Ming Liu; Ze-hui Yan; Guo-hong Deng; Qing Mao; Hui-min Liu

    doi:10.21203/rs.3.rs-32811/v1 Date: 2020-06-01 Source: ResearchSquare

    Objective: To compare the epidemiological and clinical characteristics of confirmed and suspected corona virus disease MESHD 2019 (COVID-19) cases via the process of “triage-screening-isolation-transfer” in the hospitals of non-epidemic areas.Methods: The general data, epidemiological history, clinical symptoms, laboratory examination, and chest computed tomography (CT) imaging characteristics of 38 patients with suspected COVID-19, admitted between January 21 and March 5, 2020, were analyzed.Results: According to the results of the novel severe acute respiratory syndrome MESHD coronavirus (SARS-CoV-2) ribonucleic acid (RNA) testing, the patients were divided into study group (RNA positive) and control group (RNA negative). Ultimately, 8 cases were RNA-positive and diagnosed as CDVID-19, and 30 cases were negative. Approximately half of the patients in the study group returned to Chongqing from Wuhan; this number was significantly larger than that of the control group (P<0.05). The number of subjects in close contact TRANS with the confirmed cases TRANS with SARS-CoV-2 RNA-positive and the incidence of aggregation was significantly larger in the study group than in the control group (both P<0.05). The clinical symptom of the study group was mainly low fever MESHD fever HP (with or without cough MESHD cough HP). The patients with decreased white blood SERO cells (WBC) in the study group were significantly more than those in the control group (P<0.05). Both group had reduced lymphocytes (Lym) but the number of patients with increased C-reactive protein (CRP) in the study group was significantly more than that in the control group (P<0.05). There were different degrees of chest CT abnormalities in both study and control group (P > 0.05). Conclusion: The epidemiological investigations in screening for infectious diseases MESHD is crucial. The risk of infection TRANS risk of infection TRANS infection MESHD was high from the primary epidemic area and/or in close contact TRANS with the confirmed case TRANS. The most common form of clustering occurrence was family aggregation. CDVID-19 was mainly characterized by fever MESHD fever HP and respiratory symptoms, although asymptomatic infection MESHD asymptomatic TRANS may also occur. Decreased WBC, decreased Lym, and increased CRP are common characteristics but can also be combined with other respiratory tract virus infections MESHD. COVID 19 screening by chest CT alone had certain limitations in non- epidemic areas.

    Clinical features of COVID-19 patients in one designated medical institutions in Chengdu, China

    Authors: Gui Zhou; Yun-Hui Tan; Jiang-Cuo Luo; Yi-Xiao Lu; Jing Feng; Juan Li; Yun-Mei Yang; Long Chen; Jian-Ping Zhang

    doi:10.21203/rs.3.rs-30405/v1 Date: 2020-05-19 Source: ResearchSquare

    OBJECTIVE: To study the clinical characteristics of patients infected with the 2019 severe acute respiratory syndrome MESHD coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease MESHD (COVID-2019).METHODS: Data were collected from 20 patients admitted to the Pidu District People’s Hospital in Chengdu from January 26, 2020 to March 1, 2020 with laboratory-confirmed SARS-Cov-2 infection MESHD. Clinical data were collected using the World Health Organization (WHO) nCoV CASE RECORDFORM Version 1.2 28JAN2020, which includes parameters such as: temperature, epidemiological characteristics, social network, history of exposure, and incubation period TRANS. If information was unclear, the team reviewed the original data and contacted TRANS patients directly if necessary.RESULTS: The median age TRANS of the 20 COVID-19 infected patients studied was 42.5 years. In this cohort, four patients became severely ill and one deteriorated rapidly during treatment. This patient was transferred to another medical center with an intensive care unit (ICU) for treatment. This patient died after admission to the ICU. Two of the twenty patients remained positive SARS-Cov-2 more than three weeks, and they were quarantined in a medical facility without medication. According to our analysis, all of the studied cases were infected by human-to-human transmission TRANS due to the lack of protective measures; transmission TRANS through contact within families requires confirmation. The most common symptoms at onset TRANS of illness were fever MESHD fever HP in 13 (65%) patients, cough MESHD cough HP in 9 (45%), headache MESHD headache HP in 3 (15%), fatigue MESHD fatigue HP in 6 (30%), diarrhea MESHD diarrhea HP in 3 (15%), and abdominal pain MESHD abdominal pain HP in 2 (10%). Six patients (30%) developed shortness of breath upon admission. The median time from exposure to onset of illness was6.5 days (interquartile range 3.25–9 days), and from the onset of symptoms TRANS to first hospital admission was 3.5 (1.25–7) days.CONCLUSION: Compared with patients infected with SARS-Cov-2 in Wuhan (up to the end of February 2020), the symptoms of patients in one hospital in Chengdu, Sichuan Province, were relatively mild and patients were discharged from the hospital after only a short stay. However, the fasting blood SERO glucose of the infected individuals was found to be slightly elevated because of the state of emergency MESHD. The dynamic changes in lymphocyte levels can predict disease MESHD status of COVID-19. They are also suggestive of changes in mean platelet volume during disease progression MESHD. This suggests that the patients had mild cases of COVID-19. However, because there is no effective drug treatment for COVID-19, it is important to detect and identify severe cases from mild cases early.

    REMBRANDT: A high-throughput barcoded sequencing approach for COVID-19 screening.

    Authors: Dario Palmieri; Jalal K Siddiqui; Anne Gardner; Richard Fishel; Wayne Miles

    doi:10.1101/2020.05.16.099747 Date: 2020-05-17 Source: bioRxiv

    The Severe Acute Respiratory Syndrome MESHD Coronavirus-2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV), is a highly infectious RNA virus. A still-debated percentage of patients develop coronavirus disease MESHD 2019 (COVID-19) after infection MESHD, whose symptoms include fever MESHD fever HP, cough MESHD cough HP, shortness of breath and fatigue MESHD fatigue HP. Acute and life-threatening respiratory symptoms are experienced by 10-20% of symptomatic patients, particularly those with underlying medical conditions that includes diabetes, COPD and pregnancy. One of the main challenges in the containment of COVID-19 is the identification and isolation of asymptomatic TRANS/pre-symptomatic individuals. As communities re-open, large numbers of people will need to be tested and contact-tracing TRANS of positive patients will be required to prevent additional waves of infections MESHD and enable the continuous monitoring of the viral loads COVID-19 positive patients. A number of molecular assays are currently in clinical use to detect SARS-CoV-2. Many of them can accurately test hundreds or even thousands of patients every day. However, there are presently no testing platforms that enable more than 10,000 tests per day. Here, we describe the foundation for the REcombinase Mediated BaRcoding and AmplificatioN Diagnostic Tool (REMBRANDT), a high-throughput Next Generation Sequencing-based approach for the simultaneous screening of over 100,000 samples per day. The REMBRANDT protocol includes direct two-barcoded amplification of SARS-CoV-2 and control amplicons using an isothermal reaction, and the downstream library preparation for Illumina sequencing and bioinformatics analysis. This protocol represents a potentially powerful approach for community screening, a major bottleneck for testing samples from a large patient population for COVID-19.

    Epidemic Peak for COVID-19 in India, 2020

    Authors: Chaitanya S. Wagh; Parikshit N. Mahalle; Sanjeev J. Wagh

    id:10.20944/preprints202005.0176.v1 Date: 2020-05-10 Source: preprints.org

    In India the first case of coronavirus disease MESHD 2019 (COVID-19) reported on 30 January 2020, and thereafter cases were increasing daily after the last week of Feb. 2020. COVID-19 identified as family member TRANS of coronaviridae where previously Middle East Respiratory Syndrome MESHD MERS and Severe Acute Respiratory Syndrome MESHD SARS belongs to same family. The COVID-19 attacks on respiratory system signing fever MESHD fever HP, cough MESHD cough HP and breath shortness, in severe cases may cause pneumonia MESHD pneumonia HP, SARS or some time death MESHD. The aim of this study work is to develop model which predicts the epidemic peak for COVID-19 in India by using the real-time data from 30 Jan to 10 May 2020. There are uncertainties while identifying the population information due to the incomplete and inaccurate data, we initiate the most popular model for epidemic prediction i.e Susceptible, Exposed, Infectious, & Recovered SEIR initially the compartmental model for the prediction. Based on the solution of the state estimation problem for polynomial system with Poisson noise, we estimate that the epidemic peak may reach the early-middle July 2020, initializing recovered R0 TRANS to 0 and Infected I0 to 1. The outcomes of the model will help epidemiologist to isolate the source of the disease MESHD geospatially and analyze the death MESHD. Also government authorities will be able to target their interventions for rapidly checking the spread of the epidemic.

    Anosmia HP, a Hidden Sign for COVID-19? A Case Report and Literature Review

    Authors: Karen Christelle; Maryam Mohd Zulkifli; Nani Draman

    doi:10.21203/rs.3.rs-27117/v1 Date: 2020-05-04 Source: ResearchSquare

    Background The coronavirus disease MESHD 2019 (COVID-19) is an ongoing viral pandemic that is actively affecting 210 countries worldwide, with a total of more than 1.5 million cases and 106 000 deaths MESHD. Symptoms associated with COVID-19 are mainly fever MESHD fever HP, cough MESHD cough HP, dyspnea MESHD dyspnea HP and sore throat. The current indication for COVID-19 testing includes presence of these symptoms with a positive history of travel TRANS to affected countries or contact with COVID-19 patients. Anosmia HP has been recently reported anecdotally over the past weeks as an emerging symptom of the COVID-19 but has yet to gain recognition as a symptom for COVID-19 by the World Health Organization (WHO) and Centre for Disease MESHD Control and Prevention (CDC). This case report highlights a case of isolated sudden onset of anosmia HP as a presenting symptom of COVID-19 and relevant literature review supporting the incidence of anosmia HP in COVID-19. This is a first case report of anosmia HP in COVID-19 occurring in pregnancy.Case Presentation A 30-year-old pregnant lady at 11 weeks of gestation presented with sudden onset of anosmia HP for one day with no other accompanying symptoms. She had just recovered from a mild cold a day prior to the development of anosmia HP. She had a history of travel TRANS by land to Singapore 14 days prior to onset of anosmia HP. There was no known close contact TRANS with a COVID-19 patient or attended any mass gatherings prior to development of her symptom. She underwent nasopharyngeal and oropharyngeal swab sampling which was then tested using reverse transcription polymerase chain reaction (RT-PCR) method and confirmed infection TRANS infection MESHD infection with severe HP with severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2).Conclusion Clinicians should be aware regarding anosmia HP as a presenting symptom of COVID-19 especially in the presence of risk factors such as travel TRANS to affected countries and having close contact TRANS with COVID-19 positive patients. If testing is not done, these patients should be advised for home quarantine to reduce the risk of transmission TRANS. Healthcare workers must always adhere to infection MESHD control and prevention protocol as well as personal protective equipment. 

    Early epidemiological and clinical manifestations of COVID-19 in Japan

    Authors: Muhammad Qasim; Muhammad Yasir; Waqas Ahmad; Minami Yoshida; Muhammad Azhar; Mohammad Azam Ali; Chris Wang; Maree Gould

    doi:10.1101/2020.04.17.20070276 Date: 2020-04-24 Source: medRxiv

    Background: Severe acute respiratory syndrome MESHD coronaviruses -2 (SARS-COV2) named as COVID-19 had spread worldwide and leading to 1,210,956 confirmed cases TRANS and 67,594 deaths MESHD Methods: A data of 1192 confirmed cases TRANS and 43 deaths MESHD due to COVID-19 in Japan collected from the Ministry of Health, Labour and Welfare of Japan and analysed for different epidemiological parameters and their clinical manifestations. We used Clauset-Newman-Moore (CNM) clustering algorithm to develop web-network of confirmed cases TRANS to identified clusters of community transmission TRANS. Results: Out of 1192 confirmed cases TRANS, 90.60% were symptomatic and 9.39% were asymptomatic TRANS. The prevalence SERO of COVID19 in males TRANS was 56.29% and 43.20 % in females TRANS. The mean interval (SD) from symptom onset TRANS to diagnosis was 6-22.6 days while mean interval (SD) from contact to onset of symptoms TRANS was 5-19.5 days. People of age TRANS range 40-79 were more infected and deaths MESHD median age TRANS was 80. The main symptoms were fever MESHD fever HP, dry cough MESHD cough HP, fatigue MESHD fatigue HP and pneumonia MESHD pneumonia HP. The main infected cities were Tokyo (195/1192, 16.35%), Hokkaido (160/1192 13.42%), Aichi (150/1192, 12.58%) and Osaka (145/1192, 12.16%). Only 2.34% cases had travel TRANS history from Wuhan China and Osaka music concert was identify as main cluster for community transmission TRANS. While 556 (46.64%) cases were clinically diagnosed and 557 (46.72%) were confirmed by using RT-PCR. Conclusions: Other than, declare emergency MESHD Japan need to change their approach of diagnosing COVID-19, as asymptomatic TRANS cases prevalence SERO is high and maybe it is reason for current sudden increase of cases. Screening centre should be establish away from hospitals, which are treating positive cases.

    Clinical features of COVID-19 patients in one designated medical institutions in Chengdu, China

    Authors: Gui Zhou; Yun-Hui Tan; Jiang-Cuo Luo; Yi-Xiao Lu; Jing Feng; Juan Li; Yun-Mei Yang; Long Chen; Jian-Ping Zhang

    doi:10.21203/rs.3.rs-23967/v1 Date: 2020-04-21 Source: ResearchSquare

    OBJECTIVE: To study the clinical characteristics of patients infected with the 2019 severe acute respiratory syndrome MESHD coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease MESHD (COVID-2019).METHODS: Data were collected from 20 patients admitted to the Pidu District People’s Hospital in Chengdu from January 26, 2020 to March 1, 2020 with laboratory-confirmed SARS-Cov-2 infection MESHD. Clinical data were collected using the World Health Organization (WHO) nCoV CASE RECORDFORM Version 1.2 28JAN2020, which includes parameters such as: temperature, epidemiological characteristics, social network, history of exposure, and incubation period TRANS. If information was unclear, the team reviewed the original data and contacted TRANS patients directly if necessary.RESULTS: The median age TRANS of the 20 COVID-19 infected patients studied was 42.5 years. In this cohort, four patients became severely ill and one deteriorated rapidly during treatment. This patient was transferred to another medical center with an intensive care unit (ICU) for treatment. This patient died after admission to the ICU. Two of the twenty patients remained positive SARS-Cov-2 more than three weeks, and they were quarantined in a medical facility without medication. According to our analysis, all of the studied cases were infected by human-to-human transmission TRANS due to the lack of protective measures; transmission TRANS through contact within families requires confirmation. The most common symptoms at onset TRANS of illness were fever MESHD fever HP in 13 (65%) patients, cough MESHD cough HP in 9 (45%), headache MESHD headache HP in 3 (15%), fatigue MESHD fatigue HP in 6 (30%), diarrhea MESHD diarrhea HP in 3 (15%), and abdominal pain MESHD abdominal pain HP in 2 (10%). Six patients (30%) developed shortness of breath upon admission. The median time from exposure to onset of illness was 6.5 days (interquartile range 3.25–9 days), and from the onset of symptoms TRANS to first hospital admission was 3.5 (1.25–7) days.CONCLUSION: Compared with patients infected with SARS-Cov-2 in Wuhan (up to the end of February 2020), the symptoms of patients in one hospital in Chengdu, Sichuan Province, were relatively mild and patients were discharged from the hospital after only a short stay. However, the fasting blood SERO glucose of the infected individuals was found to be slightly elevated because of the state of emergency MESHD. The dynamic changes in lymphocyte levels can predict disease MESHD status of COVID-19. They are also suggestive of changes in mean platelet volume during disease progression MESHD. This suggests that the patients had mild cases of COVID-19. However, because there is no effective drug treatment for COVID-19, it is important to detect and identify severe cases from mild cases early.

    Pregnancy during the evolving pandemic Coronavirus Disease MESHD 2019 (COVID-19): A rapid scoping review of evidence in the published literature

    Authors: Md Zabir Hasan; Gulam Muhammed Al Kibria; Tasmeer Alam

    doi:10.21203/rs.3.rs-23407/v1 Date: 2020-04-16 Source: ResearchSquare

    BackgroundWith more than 1 million confirmed cases TRANS of coronavirus disease MESHD 2019 (COVID-19) worldwide and more than 50,000 deaths MESHD, the pandemic of Severe Acute Respiratory Syndrome MESHD CoV (SARS-CoV-2) is rapidly evolving. SARS-CoV-2 can also pose a higher risk to pregnant women, due to their immunosuppression during pregnancy. This study investigates the emerging and most UpToDate published scientific literature on the clinical feature and management recommendations for pregnant women with COVID-19.MethodA wide range of published scientific literature was systematically searched from PubMed, Embase, Scopus, Web of Science, and “Global research on coronavirus disease MESHD (COVID-19)” managed by the World Health Organization, published between 1 January 2019 to 27 March 2020. No limitations were used for geographical location, and articles published in English were included in the review. Results for the eligible studies were charted, analyzed, and presented in a narrative format. ResultOur study identified 52 unique articles, and 29 of those articles were included in this review after fulltext screening. Participants were mostly in their third trimester and presented with fever MESHD fever HP, dry cough MESHD cough HP, myalgia MESHD myalgia HP, shortness, and difficulty in breathing. Ground-glass opacity in the computerized tomography scan of the chest was the cardinal feature of COVID-19 pneumonia MESHD pneumonia HP. Except for two participants, severe pneumonia MESHD pneumonia HP did not occur among pregnant women. Pregnant women with COVID-19 were treated with a wide range of antiviral drugs. Higher episodes of preterm birth and cesarean delivery were observed; however, it cannot be explicitly attributed to the SARS-CoV-2. There is no published evidence on the vertical transmission TRANS of SARS-CoV-2. Pregnancy with COVID-19 infection MESHD must be managed by a collaborative team of healthcare professionals during antenatal, delivery, or postnatal stage. Detailed contact tracing TRANS, investigating travel TRANS history, radiological assessment, and laboratory tests with regular fetal health monitoring must be done. ConclusionThe emerging evidence of higher perinatal complications puts pregnant women in a further vulnerable condition. Cautiousness is imperative during the clinical management of pregnant women with COVID-19, as there is no approved treatment regime available at this moment. More research is necessary to fill the gaps in the knowledge of the clinical spectrum of COVID-19 among pregnant women.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.